The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Risk of Alzheimer's disease and duration of NSAID use
Open accessAbstract
In a longitudinal study of 1,686 participants in the Baltimore Longitudinal Study of Aging, we examined whether the risk of Alzheimer's disease (AD) was reduced among reported users of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, we examined use of acetaminophen, a pain-relief medication with little or no anti-inflammatory activity, to assess the specificity of the association between AD risk and self-reported medications. Information on use of medications was collected during each biennial examination between 1980 and 1995. The relative risk (RR) for AD decreased with increasing duration of NSAID use. Among those with 2 or more years of reported NSAID use, the RR was 0.40 (95% confidence interval [CI]: 0.19-0.84) compared with 0.65 (95% CI: 0.33-1.29) for those with less than 2 years of NSAID use. The overall RR for AD among aspirin users was 0.74 (95% CI: 0.46-1.18), and no trend of decreasing risk of AD was observed with increasing duration of aspirin use. No association was found between AD risk and use of acetaminophen (RR = 1.35; 95% CI: 0.79-2.30), and there was no trend of decreasing risk with increasing duration of use. These findings are consistent with evidence from cross-sectional studies indicating protection against AD risk among NSAID users and with evidence suggesting that one stage of the pathophysiology leading to AD is characterized by an inflammatory process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recognition that a robust inflammatory response contributes to AD also fuelled the discovery that long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) reduced the risk for AD, delayed disease onset, and slowed cognitive decline (McGeer et al., 1996;Stewart et al., 1997;in t' in t'Veld et al., 2001).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as Stewart et al., 1997
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Bayes Estimates for the Linear Model
Lindley, D. V., & Smith, A. F. M. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00885.x · Cited by 2,025
Normal Human Aging: The Baltimore Longitudinal Study on Aging
Shock, N. W., Greulich, R. C., Costa, P. T., Andres, R., Lakatta, E. G., Arenberg, D., & Tobin, J. D. (1984) · University Libraries (University of Maryland) · doi:10.13016/sclw-iccq · Cited by 757
Inverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569
Activation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383
Stremmel, W., Strohmeyer, G. W., Borchard, F., Kochwa, S., & Berk, P. D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.4 · Cited by 350
A Population-Based Study of the Risk of Recurrence of Birth Defects
Lie, R. T., Wilcox, A. J., & Skjærven, R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407073310101 · Cited by 164
Cohler, B. J., ROBBINS, D. M., Hartman, C. R., Shader, R. I., Grunebaum, H. U., Gallant, D. H., & Weiss, J. L. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90017-5 · Cited by 132
The need for multiple time points in aging studies
Coleman, P. A., Finch, C. E., & Joseph, J. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90055-5 · Cited by 66
Research works printed but not linked: 16
- Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481-495.
- Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemical study. Acta Neuropathol (Berl) 1982;57:239-252.
- Anonymous. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
- Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
- Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 1995;45:1441-1445.
- Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
- Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6:53-60.
- Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18:70-87.
- Morris JC, Mohs R, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a Registry for Alzheimer's Disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
- Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
- Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
- Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence using the New Adult Reading Test. Cortex 1978;14:234-244.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
- Checkoway H Pearce NE Crawford-Brown DJ. Research methods in occupational epidemiology monographs in epidemiology and biostatistics vol 13. New York: Oxford University Press 1989:153-155.
- Aspirin Myocardial Infarction Study Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-669.
- Paulas HE. Nonsteroidal anti-inflammatory drugs. In: Kelley WN Harris ED Ruddy S Sledge CB eds. A textbook of rheumatology. Philadelphia: WB Saunders 1989.
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Two Hits and You’re Out? A Novel Mechanistic Hypothesis of Alzheimer Disease
Zhu, X., Perry, G. L., & Smith, M. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_19 · Cited by 4
Alzheimer’s Disease and Vascular Dementia
Nelson, L. M., Tanner, C. M., Eeden, S. K. V. D., & McGuire, V. M. (2004) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195133790.003.05 · Cited by 4
Role of Platelet Activation in Dementia
van Kooten, F., Ciabattoni, G., Patrono, C., & Koudstaal, P. J. (1998) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022431 · Cited by 4
Eicosanoids: the molecules of evolution
Lieb, J. (2001) · Medical Hypotheses · doi:10.1054/mehy.2000.1274 · Cited by 4
On the horizon: pathways for drug development in Alzheimer's disease
Hake, A. M., & Farlow, M. R. (2004) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(03)00073-9 · Cited by 4
Oncogenic parallels in Alzheimer disease
Raina, A. K., Garrett, M. R., Previll, L. A., Obrenovich, M. E., Hartzler, A., Webber, K. M., Casadesús, G., Lee, H., Perry, G. L., Zhu, X., et al. (2006) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 4
Inflammation, Anti-Inflammatory Drugs and Alzheimer’s Disease
Kawas, C. H. (1999) · Springer eBooks · doi:10.1007/978-3-642-60076-0_6 · Cited by 4
Self-citationImpact of genetic information and genetic counseling on public health
Benkendorf, J., Peshkin, B. N., & Lerman, C. E. (2000) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195128307.003.0019 · Cited by 4
Non-Steroidal Anti-Inflammatory Drug Use and Essential Tremor
Pan, J., Michalec, M., & Louis, E. D. (2014) · Neuroepidemiology · doi:10.1159/000366424 · Cited by 3
Agrawal, N. K., Singh, S. K., Singh, N., Kalra, S., & Srivastava, G. (2010) · The Internet Journal of Geriatrics and Gerontology · doi:10.5580/981 · Cited by 5
Alzheimer's Disease: Clinical Trials and Future Perspectives
Lee, K. S., & Suh, H. S. (2012) · 대한정신약물학회지 · Cited by 2
Patil, S. P., DiFlumeri, J., Wellington, J., Fattakhova, E., & Oravic, M. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110865 · Cited by 3
Aspirin and anti-inflammatory drugs for the prevention of dementia
Jordan, F., McGuinness, B., Murphy, K., Passmore, P., Kelly, J. P., & Devane, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011459 · Cited by 3
Polyunsaturated Fatty Acids and Neuro-Inflammation
Layé, S., & Dantzer, R. (2006) · Humana Press eBooks · doi:10.1385/1-59259-952-4:353 · Cited by 3
Huang, Y., Erdmann, N. B., Hexum, T. D., & Zheng, J. (2008) · Springer eBooks · doi:10.1007/978-0-387-72573-4_15 · Cited by 3
Selective modulation of muscarinic receptor subtypes: therapeutic potential
Eglen, R. M., & Hegde, S. S. (1998) · Emerging Drugs · doi:10.1517/14728214.3.1.67 · Cited by 3
Cyclooxygenase‐2 inhibitors: Do they have a role in emergency department prescribing?
Wilton, T. (2004) · Emergency Medicine Australasia · doi:10.1111/j.1742-6723.2004.00540.x · Cited by 3
McRae‐Degueurce, A., & Ling, E. (2003) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.3.2.247 · Cited by 3
My health: whose responsibility? Low-dose aspirin and older people
Elwood, P. C., Longley, M. J., & Morgan, G. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.5.755 · Cited by 3
Is there a role fordiet in cognitive rehabilitation?
Parrott, M. D., & Greenwood, C. E. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9781316529898.020 · Cited by 3
Beta Amyloid Protein Clearance and Microglial Activation
Frautschy, S. A., Cole, G. M., & Ard, M. D. (2002) · Springer eBooks · doi:10.1007/978-1-4757-4139-1_12 · Cited by 3
Wiltfang, J., Trost, S., & Hampel, H.-J. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_59 · Cited by 3
Weggen, S., Czirr, E., Leuchtenberger, S., & Eriksen, J. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_11 · Cited by 3
Introduction The Promise of Coxibs
Schumacher, H. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00367-6
The Role of Oxidative Stress in the Pathological Sequelae of Alzheimer Disease
Smith, M. A., & Perry, G. L. (1998) · Springer eBooks · doi:10.1007/978-1-4757-2907-8_19 · Cited by 3
Predicting Who Will Develop Alzheimer’s Disease
Mayeux, R. P. (1999) · Springer eBooks · doi:10.1007/978-3-642-60076-0_2 · Cited by 3
COX-2-Inhibitoren: Aktueller Stand und Ausblick
Dannhardt, G., & Hahn, L. (2000) · Pharmazie in unserer Zeit · doi:10.1002/(sici)1615-1003(200002)29:2 · Cited by 3
McGoldrick, K. E. (2004) · Survey of Anesthesiology · doi:10.1097/01.sa.0000132028.95631.1d · Cited by 3
Challenges and Directions for Gerontological Research Beyond 2000
Wetle, T. T. (1998) · Australian Journal on Ageing · doi:10.1111/j.1741-6612.1998.tb00879.x · Cited by 3
Detangling Alzheimer’s Disease
Helmuth, L. L. (2001) · Science of Aging Knowledge Environment · doi:10.1126/sageke.2001.1.oa2 · Cited by 3
Alzheimer's Disease and Mild Cognitive Impairment
Jones, D. T., Bruns, M. B., & Petersen, R. C. (2018) · Wiley eBooks · doi:10.1002/9781118772034.ch21 · Cited by 3
Peng, K.-P., & Chang, K. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00028 · Cited by 2
Yoga as a therapeutic intervention for the management of neurodegenerative disorders
Nadholta, P., Choudhary, S. K., & Rain, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19084-1.00021-1 · Cited by 2
Roles of Innate Immunity and Inflammation in the Aging Brain
Okun, E., Chen, X., Bašta, M., & Mattson, M. P. (2011) · Oxidative stress and disease · doi:10.1201/b11014-2 · Cited by 2
Andreasson, K. I., & Montine, T. J. (2007) · Springer eBooks · doi:10.1007/978-0-387-73894-9_6 · Cited by 3
Medications and Cognition in Older Adults
Caporaso, G. L. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3106-0_7 · Cited by 2
Tratamiento del deterioro cognitivo leve
Carretero, M. (2003) · Offarm: farmacia y sociedad · Cited by 2
Matysiak, W., & Jodłowska‐Jędrych, B. (2010) · PROTOPLASMA · doi:10.1007/s00709-010-0194-9 · Cited by 2
Nouveaux anti-inflammatoires non stéroïdiens: donneurs de NO et inhibiteurs sélectifs de COX-2
Bannwarth, B., & Berenbaum, F. (1999) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(99)80506-2 · Cited by 2
Martín‐Sánchez, F. J., Díaz, S. P. R., & Gregório, P. G. (2003) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(03)71069-5 · Cited by 2
Aβ-Induced Proinflammatory Cytokine Release from Differentiated Human THP-1 Monocytes
Brunden, K. R., Kocsis‐Angle, J., Embury, P., & Yates, S. L. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:101 · Cited by 2
The Amyloid _-Protein and Alzheimer's Disease
Teplow, D. B., Yang, M., Roychaudhuri, R., Pang, E. S., Huynh, T. V., Chen, M., & Beroukhim, S. (2012) · Frontiers in neuroscience · doi:10.1201/b11986-2 · Cited by 2
Effect of Curcumin and Vitamin D3 on Learning and Cognition Inrat Model of Alzheimer’s Disease
Khan, S. (2017) · Austin Journal of Cerebrovascular Disease & Stroke · doi:10.26420/austinjcerebrovascdisstroke.2017.1060 · Cited by 2
Ideational Fluency in Patients with Rheumatoid Arthritis
Mednieks, J., Naumovs, V., & Šķilters, J. (2020) · Current Rheumatology Reviews · doi:10.2174/1573397116666201119145640 · Cited by 2
Asthana, A., Agarwal, R., & Tripathi, S. (2023) · Advances in Alzheimer s Disease · doi:10.4236/aad.2023.122002 · Cited by 2
Managing Alzheimer's Disease in the New Health Care Economy
Kettl, P. A. (2003) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1023/a:1023536527428 · Cited by 2
Antioxidant Genes and Reactive Oxygen Species in Down's Syndrome
Bladier, C., de Haan, J. B., & Kola, I. (2000) · Elsevier eBooks · doi:10.1016/b978-012636670-9/50021-0 · Cited by 2
Microglial and Astrocytic Reactions in Alzheimer’s Disease
Walker, D. G., & Beach, T. G. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-105-3_19 · Cited by 2
Antiplatelet Drugs in the Elderly
Green, D., & Podrazik, P. M. (2000) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1018646214206 · Cited by 2
Role of Calcium in Inflammation: Relevance to Alzheimer's Disease
Quadros, A. (2007) · doi:10.25148/etd.fi10022540 · Cited by 2
Jorm, A. F. (2003) · Wiley eBooks · doi:10.1002/9780470752340.ch39 · Cited by 2
Clinical Applications of Aspirin
Schrör, K. (2008) · Wiley eBooks · doi:10.1002/9783527625994.ch4 · Cited by 2
Ibuprofen in Prevention of Neurodegenerative Diseases
Rainsford, K. D. (2015) · Wiley eBooks · doi:10.1002/9781118743614.ch14 · Cited by 2
The clinical developments and future of the COX-2 inhibitor drugs
Goldstein, J. (2001) · Inflammopharmacology · doi:10.1163/156856001300248362 · Cited by 2
Easing the burden of Alzheimer's disease: therapeutic options
Baumel, B. S. (1998) · European Journal of Neurology · doi:10.1111/j.1468-1331.1998.tb00445.x · Cited by 2
Prettyman, R. J. (2007) · BMJ · doi:10.1136/bmj.39220.421262.3a · Cited by 2
Part VI. Primary drug therapies for alzheimer's disease
Knopman, D. S. (2000) · Disease-a-Month · doi:10.1016/s0011-5029(00)90007-5 · Cited by 2
Pharmacology and the Older Person: Effects on Communication
Vogel, D., & Carter, P. (1998) · Topics in Geriatric Rehabilitation · doi:10.1097/00013614-199812000-00008 · Cited by 2
Advances in Methodology and Current Prospects for Primary Drug Therapies for Alzheimer's Disease
Knopman, D. S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:45 · Cited by 2
Abdel‐Aal, R. A., Hussein, O. A., Elsaady, R. G., & Abdelzaher, L. A. (2021) · Research Square · doi:10.21203/rs.3.rs-831722/v1 · Cited by 2
Mayeux, R. P., & Gandy, S. (2000) · Elsevier eBooks · doi:10.1016/b978-012288145-9/50112-1 · Cited by 3
Over-the-Counter (OTC) Drugs and Some Prescription Drugs
Schuckit, M. A. (2000) · Springer eBooks · doi:10.1007/978-1-4757-3232-0_11 · Cited by 2
Preventive Effects of Dairy Products on Dementia and Cognitive Decline
Yun, J.-H., Seol, K., Yoo, J., Oh, M., & Ham, J.-S. (2020) · Journal of Dairy Science and Biotechnology · doi:10.22424/jdsb.2020.38.1.27 · Cited by 1
Medications and Cognition in Older Adults
Caporaso, G. L. (2019) · Clinical handbooks in neuropsychology · doi:10.1007/978-3-319-93497-6_10 · Cited by 1
Síntesis de nuevos derivados del naftaleno
Rivera-Marrero, S., Sablón-Carrazana, M., López-Barroso, R. M., Pérez-Perera, R., Perera‐Pintado, A., Capote, A. P., Garrido, R., Sánchez-Puente, A., & Rodríguez‐Tanty, C. (2011) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 1
Peroxisome Proliferator-Activated Receptor Gamma Agonists
Landreth, G. E., Sundararajan, S., & Heneka, M. T. (2003) · Humana Press eBooks · doi:10.1007/978-1-59259-297-5_7 · Cited by 3
Complement Component (3b/4b) Receptor 1 (CR1)
Lord, J., & Morgan, K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7309-1_5 · Cited by 1
Nutritional Modulation of Neurodegenerative Disorders
Yost, H., & Kligman, E. W. (2010) · CRC Press eBooks · doi:10.1201/9781420039047-32 · Cited by 1
Alzheimer’s disease: An update on pathophysiology and pharmacotherapy
Chopra, S. S., Negi, R. S., & -, V. (2020) · Journal of Science and Technological Researches · doi:10.51514/jstr.2.4.2020.19-24 · Cited by 1
The Role of Adaptive and Innate Immunity in Alzheimer’s Disease
Holmes, C. (2021) · Cambridge University Press eBooks · doi:10.1017/9781108539623.012 · Cited by 1
Lord, J., & Morgan, K. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7309-1_3 · Cited by 1
Structural Scaffolds as Anti- Alzheimer Agents
Alka, T., Sati, B., & Chaudhary, A. (2022) · Medicinal Chemistry · doi:10.2174/1573406418666220815101124 · Cited by 1
Asthana, A., Tripathi, S., & Agarwal, R. (2023) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2023-2467 · Cited by 2
Agnes Preethy, H., Venkatakrishnan, Y. B., Ramakrishnan, V., & Krishnan, U. M. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2322612 · Cited by 1
Pattern Recognition Receptors and Aging
Shalaby, K. H. (2013) · Springer eBooks · doi:10.1007/978-3-642-39495-9_8 · Cited by 1
McGeer, P. L., Schulzer, M., & McGeer, E. G. (2001) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8350-4_2 · Cited by 1
Mouse Models of Alzheimer’s Disease
German, D. C. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_16 · Cited by 1
Alzheimer’s Disease: Beyond the Neuron
Verma, A., & Zabel, M. K. (2018) · InTech eBooks · doi:10.5772/intechopen.75510 · Cited by 1
O’Brien, K., & Blair, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-78559-8_9 · Cited by 1
Neurodegenerative and movement disorders
(2012) · CRC Press eBooks · doi:10.1201/b13258-14 · Cited by 1
Huang, Y., & Zheng, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-44022-4_17 · Cited by 1
Current and Future Therapies for Alzheimer Disease
Chakrabarty, P., Das, P., & Golde, T. E. (2010) · Wiley eBooks · doi:10.1002/9780470572702.ch34 · Cited by 1
Leighty, R. E. (2009) · Digital Commons - University of South Florida (University of South Florida) · Cited by 1
The eicosanoid pathway and brain aging
Manev, H., & Uz, T. (2003) · Advances in cell aging and gerontology · doi:10.1016/s1566-3124(03)12007-x · Cited by 1
Versijpt, J. J. (2003) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1
Neurodegeneration and Loss of Cell Cycle Control in Postmitotic Neurons
York, R. D., Cicero, S. A., & Herrup, K. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-021-8_21 · Cited by 1
Aging and Cognitive Decline: Neuroprotective Strategies
do Couto, F. S., & de Mendonça, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-70830-0_11 · Cited by 1
Current and the near future medications for Alzheimer's disease: What can we expect from them?
Shua‐Haim, J. R., & Ross, J. (1999) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331759901400507 · Cited by 1
Multiple anti‐Alzheimer disease activities of non‐steroidal anti‐inflammatory drugs
Morihara, T., Cole, G. M., TANII, H., Tanaka, T., Kudo, T., & Takeda, M. (2006) · Psychogeriatrics · doi:10.1111/j.1479-8301.2006.00139.x · Cited by 1
Frontiers in Neuropharmacotherapy Part I: Alzheimer’s Disease and Epilepsy
Chappell, J. C., & Cohen, H. (2002) · Journal of Pharmacy Practice · doi:10.1106/37dx-47ha-vfdx · Cited by 1
Pasinetti, G. M. (2002) · Drug Development Research · doi:10.1002/ddr.10096 · Cited by 1
Treatments for vascular dementia and Alzheimer's disease.
Kitamura, S. (1999) · Journal of Nippon Medical School · doi:10.1272/jnms.66.52 · Cited by 1
Application of the Changing Therapies for Alzheimer's Disease in Clinical Practice
Sabbagh, M. N. (1998) · Perspectives on Gerontology · doi:10.1044/gero3.1.7 · Cited by 1
Vasoactivity of Amyloid β Peptides
Paris, D., Town, T., & MULLAN, M. J. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_17 · Cited by 1
Are the benefits of NSAIDs to decrease the risk of Alzheimer's disease a MIRAGE?
Standridge, J. B. (2005) · Therapy · doi:10.1586/14750708.2.3.375 · Cited by 1
WORK GROUP ON ALZHEIMER'S DISEASE AND OTHER DEMENTIAS
Rabins, P. V., Rovner, B. W., Rummans, T. A., Schneider, L. S., Tariot, P. N., & Blass, D. M. (2010) · Cited by 1
All the things that aspirin does
Flower, R. (2003) · BMJ · doi:10.1136/sbmj.0310368 · Cited by 1
Wills, W., Trieman, N., & Leff, J. (1998) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199804)13:4
Metadata
- Authors
- Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J.
- Affiliations
- Johns Hopkins University (US)
- Venue
- Neurology
- Published
- 1997-03
- Volume
- 48
- Issue
- 3
- Pages
- 626-632
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2163110760
- Cited by
- 1,132
- References
- 16
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 13 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 23 · 2019: 22 · 2018: 21 · 2017: 24 · 2016: 28 · 2015: 29 · 2014: 32 · 2013: 24 · 2012: 31
- FWCI
- 42.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- American Academy of Neurology
- National Institutes of Health
- National Institute on Aging (R01AG008325, R01-AG08325)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- Alzheimer's disease, nonsteroidal anti-inflammatory drugs, aspirin, paracetamol, medication use, neuroprotection, neuroinflammation
- MeSH terms
- Acetaminophen, Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Confidence Intervals, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
